SOLV Quote, Financials, Valuation and Earnings

Biolase has a net margin of 6.62% compared to Solventum's net margin of -13.16%. Solventum's return on equity of 11.75% beat Biolase's return on equity of -21668.17%.

Solventum has a consensus price target of $81.27, signalling upside risk potential of 11.19%. On the other hand Biolase has an analysts' consensus of $1.2000 which suggests that it could grow by 19336.35%. Given that Biolase has higher upside potential than Solventum, analysts believe Biolase is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biolase has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.394%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biolase offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Biolase pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Biolase quarterly revenues of $10.9M. Solventum's net income of $137M is higher than Biolase's net income of -$1.4M. Notably, Solventum's price-to-earnings ratio is 33.84x while Biolase's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.53x versus 0.01x for Biolase. Usually stocks with elevated PS ratios are considered overvalued.

Milestone Scientific has a net margin of 6.62% compared to Solventum's net margin of -89.35%. Solventum's return on equity of 11.75% beat Milestone Scientific's return on equity of -79.98%.

Solventum has a consensus price target of $81.27, signalling upside risk potential of 11.19%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 130.34%. Given that Milestone Scientific has higher upside potential than Solventum, analysts believe Milestone Scientific is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Milestone Scientific quarterly revenues of $2.2M. Solventum's net income of $137M is higher than Milestone Scientific's net income of -$2M. Notably, Solventum's price-to-earnings ratio is 33.84x while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.53x versus 8.58x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of 6.62% compared to Solventum's net margin of 2.92%. Solventum's return on equity of 11.75% beat Envista Holdings's return on equity of -34.78%.

Solventum has a consensus price target of $81.27, signalling upside risk potential of 11.19%. On the other hand Envista Holdings has an analysts' consensus of $19.04 which suggests that it could grow by 4.22%. Given that Solventum has higher upside potential than Envista Holdings, analysts believe Solventum is more attractive than Envista Holdings.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.472%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Envista Holdings quarterly revenues of $616.9M. Solventum's net income of $137M is higher than Envista Holdings's net income of $18M. Notably, Solventum's price-to-earnings ratio is 33.84x while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.53x versus 1.26x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of 6.62% compared to Solventum's net margin of 2.28%. Solventum's return on equity of 11.75% beat Dentsply Sirona's return on equity of -35.57%.

Solventum has a consensus price target of $81.27, signalling upside risk potential of 11.19%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 13.54%. Given that Dentsply Sirona has higher upside potential than Solventum, analysts believe Dentsply Sirona is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.642%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.01% to investors and pays a quarterly dividend of $0.16 per share. Solventum pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Dentsply Sirona quarterly revenues of $879M. Solventum's net income of $137M is higher than Dentsply Sirona's net income of $20M. Notably, Solventum's price-to-earnings ratio is 33.84x while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.53x versus 0.86x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.